Microbiota as a biomarker of tuberculosis treatment response: association with clinical history, inflammation and outcome

For decades, the standard treatment for tuberculosis has been a rigorous regimen of four antibiotics taken daily for at least six months. This approach is necessary because the bacteria causing the disease are stubborn and require prolonged exposure to medicine to be fully eradicated. However, antibiotics are not precise surgeons; they do not target only the harmful invaders. They also sweep through the body's vast community of harmless and beneficial microbes, known as the microbiota, which live in our gut and respiratory tract. These microscopic residents play a crucial role in training our immune system and keeping our bodies functioning smoothly. While scientists have long known that short-term antibiotic use can disturb this delicate ecosystem, it has remained unclear what happens in the long run. Does the community bounce back to its original state once the medicine stops, or does the treatment leave a permanent scar? Understanding this is vital, because a disrupted microbiome has been linked to other serious health issues, and knowing how it recovers—or fails to recover—could reveal new clues about why some patients heal quickly while others struggle.

A team of researchers set out to map this long-term journey by following 107 people diagnosed with active tuberculosis and 180 of their close household contacts who did not have the disease. The scientists collected samples of sputum and stool from these individuals at the start of treatment, and then again at two, six, twelve, and eighteen months. They also measured levels of various immune signaling proteins in the blood to see how the body's inflammation responded over time. By comparing the microbial communities of the patients against their healthy contacts, and tracking how these communities changed as the antibiotics were administered and then stopped, the researchers could see the true impact of the treatment on the body's internal ecosystem.

The study revealed that the treatment acts as a powerful reset button, but the recovery process is different for the lungs and the gut. In the sputum, which represents the lungs, the diversity of microbes dropped sharply during the first two months of treatment. However, this was a temporary dip. By the time patients reached the six-month mark, the lung microbiome had largely returned to its pre-treatment state, and by eighteen months, it was indistinguishable from the baseline. The gut, represented by stool samples, told a different story. While the diversity of gut microbes also fell during the first two months, it took much longer to recover. Even a full year after the treatment ended, the gut microbiome of the patients still looked different from that of their healthy contacts. Specifically, certain beneficial groups of bacteria that help regulate the immune system remained depleted, while other types of bacteria that are usually rare became more common. These changes persisted long after the antibiotics were gone, suggesting the gut ecosystem had been permanently altered by the course of treatment.

The researchers also discovered that these microbial patterns could serve as a warning system for how well a patient was responding to therapy. Those who had a difficult time clearing the infection showed distinct differences in their microbial makeup compared to those who recovered smoothly. For instance, patients with unfavorable outcomes had sputum that was enriched with specific bacteria like Pseudomonas and lacked others like Porphyromonas. In the gut, those who did not recover well showed an overabundance of certain bacteria and a lack of others, even before the treatment was finished. Furthermore, the study found that the way a person's microbiome changed over time was linked to their medical history. People who had been treated for tuberculosis before were more likely to follow a trajectory where their microbial diversity continued to decline or failed to recover, suggesting that previous exposure to these drugs might make the microbiome more fragile and less able to bounce back.

Perhaps most surprisingly, the connection between these gut bacteria and the body's immune response lasted long after the treatment ended. The researchers found that specific bacteria in the stool remained tightly linked to levels of inflammation in the blood, even eighteen months after the patients had finished their medication. This suggests that the gut microbiome is not just a passive victim of antibiotic treatment but an active player in the body's long-term immune health. While the lungs seemed to heal and return to normal relatively quickly, the gut carried the memory of the treatment for much longer. These findings suggest that monitoring the microbiome could one day help doctors predict who is at risk of a poor outcome or who might need additional support to ensure their immune system recovers fully. The study does not yet prove that fixing the microbiome will cure tuberculosis, but it highlights that the body's microbial community is a lasting record of the battle against the disease, offering new potential clues for improving how we treat and monitor patients in the future.